Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 6 Genitourinary 3 Sarcoma 2 Tumor-Agnostic 1 Thoracic 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1 Gynecologic 1 CNS 1

Conditions

Neoplasm Metastasis 1 Endometrial Neoplasms 1

Interventions

Paclitaxel 140 pembrolizumab 119 Carboplatin 104 Bevacizumab 90 Cisplatin 67 Specimen Handling 62 Magnetic Resonance Spectroscopy 51 olaparib 50 Gemcitabine 39 Nivolumab 36 Biopsy 36 liposomal doxorubicin 32 Taxes 31 Cyclophosphamide 31 Blood Specimen Collection 29 niraparib 27 lenvatinib 26 Letrozole 26 Doxorubicin 26 Topotecan 25 Drug Therapy 25 Immunoglobulin G 22 fludarabine 21 atezolizumab 21 Radiotherapy 21 Brachytherapy 21 Disulfides 20 durvalumab 19 Surveys and Questionnaires 19 dostarlimab 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

pemigatinib × Gynecologic × 1 year × Clear all

NCT04463771 2025-12-10

POD1UM-204

Incyte Corporation

Phase 2 Active not recruiting

Neoplasm Metastasis, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡